Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | S100A4 | P26447 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12286918 | 0.82 | HSD17B10 (0.52) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL25310 | 0.80 | HSD17B10 (0.50) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL29382907 | 0.78 | VCAM1 (0.56) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL5671061 | 0.78 | HSD17B10 (0.54) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL29595518 | 0.78 | HSD17B10 (0.48) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL562027 | 0.78 | HSD17B10 (0.48) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL56638 | 0.78 | VCAM1 (0.56) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL10870335 | 0.78 | KMT2A (0.50) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL11055565 | 0.78 | HSD17B10 (0.48) | HSD17B10TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL11684809 | 0.78 | HSD17B10 (0.48) | HSD17B10TDP1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408060-B2 | Nonsteroidal progesterone receptor modulators | SCHERING AG (DE) | 2008-08-05 | — | — | US | claimed |
| EP-1902049-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-1899315-A1 | BENZOFURANONE DERIVATIVES AS NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | Schering Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| US-20070142464-A1 | Nonsteroidal progesterone receptor modulators | SCHERING AG (DE) | 2007-06-21 | — | — | US | claimed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | claimed |
| WO-2006136462-A1 | BENZOFURANONE DERIVATIVES AS NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| WO-2006136461-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| EP-0240890-B1 | Prostacyclin (PGI2) analogues | SHIONOGI & CO (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-4855449-A | Prostacyclin (PGI2) analogues | SHIONOGI & CO., LTD. (JP) | 1989-08-08 | — | — | US | disclosed |
| US-4820836-A | ANTICOAGULANTS, ANTIULCER AGENTS | SHIONOGI & CO., LTD. (JP) | 1989-04-11 | — | — | US | disclosed |
| EP-0240890-A2 | Prostacyclin (PGI2) analogues | SHIONOGI & CO., LTD. (JP) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, CYP19A1 | HSD17B10 364/4885TDP1 3156/4885ALDH1A1 1444/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | HSD17B10 2922/4885TDP1 494/4885ALDH1A1 3061/4885 |
| US-20070142464-A1 | Nonsteroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | HSD17B10 447/4885TDP1 3346/4885ALDH1A1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.